Last reviewed · How we verify

Traxam (FELBINAC)

Phase 3 active Small molecule

Traxam (generic name: FELBINAC) is a felbinac drug. It is currently in Phase 3 development for Osteoarthritis, Pain.

Traxam works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.

Traxam, also known as Felbinac, is a small molecule drug that targets Prostaglandin G/H synthase 1. It is used to treat osteoarthritis and pain. The commercial status of Traxam is unclear, but it is classified as a felbinac drug class. As a non-steroidal anti-inflammatory drug (NSAID), Traxam works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Likelihood of approval
59.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Immunology slight uplift +1.0pp
    Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameFELBINAC
Drug classfelbinac
TargetProstaglandin G/H synthase 1
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Imagine your body has a factory that produces chemicals called prostaglandins, which are like messengers that tell your brain that you're in pain. Traxam is like a factory worker who stops the production of these messengers, reducing the pain and inflammation. This helps to relieve the symptoms of osteoarthritis and pain.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Traxam

What is Traxam?

Traxam (FELBINAC) is a felbinac drug, indicated for Osteoarthritis, Pain.

How does Traxam work?

Traxam works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.

What is Traxam used for?

Traxam is indicated for Osteoarthritis, Pain.

What is the generic name of Traxam?

FELBINAC is the generic (nonproprietary) name of Traxam.

What drug class is Traxam in?

Traxam belongs to the felbinac class. See all felbinac drugs at /class/felbinac.

What development phase is Traxam in?

Traxam is in Phase 3.

What does Traxam target?

Traxam targets Prostaglandin G/H synthase 1 and is a felbinac.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing